Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
The Walter Reed Army Institute of Research this week administered the first vaccine in a Phase 1 clinical trial to evaluate the safety and immunogenicity of a Marburg vaccine candidate in healthy adult volunteers.
Lassa fever belongs to the same class of hemorrhagic fevers as Ebola. Like Ebola, it has been a major health threat in Western Africa, infecting 100,000-300,000 people and killing 5,000 per year.
A synthetic DNA vaccine has been shown to provide complete and enduring protection from Ebola virus in preclinical studies.
African swine fever virus threatens to devastate the swine industry and is positioned to spread throughout Asia. The virus has spread throughout the Caucuses region of Eastern Europe and was reported in China in August. It recently was detected in wild boar in Belgium.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided "100% protection against a lethal dose of the Ebola virus" in a recent animal study published in The Journal of Infectious Diseases.
The outbreak of the deadly Ebola in the Democratic Republic of Congo has spread outside the province of North Kivu according to a statement made by the country’s health ministry yesterday. With this the viral infection has reached an active conflict zone and this may mean that it could spread wider now.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell.
The strategy used by the Oropouche virus to replicate in human cells has been described for the first time by researchers at the University of São Paulo in Brazil and international collaborators in an article published in the journal PLOS Pathogens.
A research team from several institutions being led by the University of California San Diego has deciphered a key component behind a rising epidemic of pathogens that the World Health Organization (WHO) recently added to its list of critical emerging diseases.
In a new study, researchers at Uppsala University and other institutions have identified genetic material from the recently identified Alkhurma hemorrhagic fever virus in the tick species Hyalomma rufipes. The discovery was made after thousands of ticks were collected from migratory birds captured in the Mediterranean basin. The results indicate that birds could contribute to spreading the virus to new geographical areas.
Congo is facing a new Ebola outbreak and the health officials have announced that starting today, (Monday 21st May 2018), response teams would begin administering an experimental Ebola vaccine in Mbandaka.
There has been a confirmed case of Ebola in the Mbandaka city of Congo that has a population of 1.2 million. This is the first urban case in the latest outbreak and is being considered to be one of the most serious ones in recent times. The last major outbreaks have affected people across West Africa between 2014 and 2016.
Hemorrhagic fever viruses, so named for their ability to induce massive, and at times fatal, internal bleeding, captured the world's attention during the Ebola outbreak of 2014-2016 in West Africa.
The Centers for Disease Control and Prevention (CDC) has released a new report warning people about the myriad of diseases that are transmitted via bites of blood-sucking insects such as ticks, mosquitoes and fleas calling it a “growing health problem” in the United States.
Crimean-Congo hemorrhagic fever is a viral disease spread by ticks in the Middle East, Asia, Africa and parts of Europe. Infection with CCHF virus is fatal in nearly one of every three cases.
Scientists have identified potential biomarkers in nonhuman primates exposed to Ebola virus (EBOV) that appeared up to four days before the onset of fever, according to research published today in the journal Science Translational Medicine.
Nigeria has been affected with an outbreak of the deadly Lassa fever since the start of this year. This disease typically has a high rate of fatality, no known cure and no vaccines have been developed against it yet. This is an unprecedented outbreak of this disease that is spreading faster than before. It is infecting more individuals than health workers can handle with their limited resources, say official sources.
BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, announced today its collaboration with Biosensorix, a Singapore-based company in the field of medical diagnostics, to develop next-generation, quantitative, point-of-care diagnostics based on research conducted at Ben-Gurion University.
As globalization and climate change spread tropical infectious diseases around the globe, not all populations have the same degree of susceptibility.
For a long time, a dengue vaccine was the holy grail in dengue research. Now that a dengue vaccine is finally on the market (Sanofi's Dengvaxia), other issues have arisen, such as what happens in the babies of vaccinated mothers.